Life science companies require a cash infusion at least twice as big as that of 2018 to fund research and development at a time when investors remain skittish, according to a Bloomberg analysis. … READ MORE >
Economic News from RSM
Life science companies require a cash infusion at least twice as big as that of 2018 to fund research and development at a time when investors remain skittish, according to a Bloomberg analysis. … READ MORE >